Long-term (5-8 years) follow-up of Solcoderm-treated malignant skin tumors.
Long-term follow-up shows a low recurrence rate for Solcoderm treated small superficial basal cell epithelioma, and a high recurrence rate for larger malignant skin lesions.
D000085:Acetates / Q000627:therapeutic use; D019342:Acetic Acid; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D002277:Carcinoma / Q000188:drug therapy*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003300:Copper / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007773:Lactates / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local; D009566:Nitrates / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*
D000085:Acetates; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; D007773:Lactates; D009566:Nitrates; D003300:Copper; D019342:Acetic Acid